Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 4 of the 21 sources its claims cite were checked for support.
Abstract
The misfolding and accumulation of tau protein into intracellular aggregates known as neurofibrillary tangles is a pathological hallmark of neurodegenerative diseases such as Alzheimer’s disease. However, while tau propagation is a known marker for disease progression, exactly how tau propagates from one cell to another and what mechanisms govern this spread are still unclear. Here, we report that cellular internalization of tau is regulated by quaternary structure and have developed a cellular assay to screen for genetic modulators of tau uptake. Using CRISPRi technology we have tested 3200 genes for their ability to regulate tau entry and identified enzymes in the heparan sulfate proteoglycan biosynthetic pathway as key regulators. We show that 6- O -sulfation is critical for tau-heparan sulfate interactions and that this modification regulates uptake in human central nervous system cell lines, iPS-derived neurons, and mouse brain slice culture. Together, these results suggest novel strategies to halt tau transmission.
Overview
CoChat Summary
TL;DR
Tau internalization is regulated by quaternary structure, with monomer, oligomer, and sonicated fibrils taken up efficiently while intact fibrils are not. A CRISPRi screen identified heparan sulfate proteoglycan biosynthetic enzymes, and 6-O-sulfation on heparan sulfate was critical for tau binding and uptake across CNS cell lines, iPS-derived neurons, and mouse brain slice culture.
Key findings
- Tau uptake depended on size/quaternary structure: DLS showed monomer at 5.7 ± 0.9 nm, oligomers at 19 ± 3 nm, sonicated fibrils at 33 ± 11 nm, and fibrils at 80 ± 8 nm; H4 cells and iPS-derived neurons internalized monomer, oligomer, and sonicated fibrils efficiently, but fibrils showed nearly no uptake.
- A CRISPRi screen of 3200 genes with five sgRNAs per gene identified HSPG biosynthesis genes EXT2 and HS6ST1 and endocytosis gene DNM2; single knockdowns repressed tau monomer uptake by over 50%, also reduced oligomer uptake, and reduced tau uptake in iPS-derived neurons.
- Heparin ELISA showed tau bound heparin with affinity 4.6 ± 0.6 nM, oversulfated heparin at 2.2 ± 0.5 nM, fully desulfated heparin >1 μM, N-desulfated heparin 15.0 ± 5 nM, 2-O-desulfated heparin 7.4 ± 1.0 nM, and 6-O-desulfated heparin >1 μM; relative binding of 6-O-desulfated heparin at 10 nM tau was 6.9% that of heparin.
- Competition with soluble heparin derivatives reduced tau uptake in H4 cells, iPS-derived neurons, and mouse slice culture; 6-O-desulfated heparin and chondroitin sulfate were less effective. Overexpression of Sulf1 reduced uptake to 17 ± 9% and Sulf2 to 36 ± 15%.
Methods
- Recombinant full-length 2N4R tau was purified, labeled with AF488 or AF647, and prepared as monomer, oligomer, sonicated fibril, or fibril using heparin; constructs were characterized by non-reducing SDS-PAGE, TEM, and DLS. Uptake was measured by flow cytometry in H4, SHSY-5Y, ReN VM, and iPS-derived neurons, with 4 °C controls subtracted, and by imaging in mouse brain slice culture.
- For the CRISPRi screen, H4 cells expressing dCas9-KRAB were transduced with a next-generation sgRNA library targeting 3200 genes with five sgRNAs per gene plus non-targeting controls, incubated with 25 nM AF488-labeled 2N4R monomer for 1 h, sorted into top and bottom thirds of fluorescence, and sgRNA abundance was determined by next-generation sequencing; significance was calculated using the Mann-Whitney U test against 280 non-targeting sgRNAs.
- Binding and validation used a heparin ELISA with biotinylated heparin derivatives and myc-tagged 2N4R, Hill binding model fitting, cellular competition with soluble heparin derivatives, Sulf1/Sulf2 overexpression, qPCR, immunocytochemistry, and HPLC disaccharide analysis.
Limitations
- The paper states that this work focused only on uptake of “naked” tau and did not address seeding potential or possible exosome transfer of fibrils between neurons; it also states that further work is needed to understand whether specific HS chain lengths or regions on tau are important for the interaction.
- The paper states that further work will be needed to dissect if and how cell cycle regulator hits influence post-mitotic neurons.
- Evident from the text: the primary CRISPRi screen used monomeric tau in an H4 cell line, so the screen may not capture all regulators of oligomer or fibril uptake; validation was limited to selected genes, and the ex vivo mouse slice data rely on imaging/median fluorescence rather than mechanistic dissection.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
3 Valid · 0 Not valid · 13 Not checked · 44 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tau bound heparin with an affinity of 4.6 ± 0.6 nM, consistent with previous reports26.”
§ Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) > Results > Tau binds to heparin derivatives and shows specificity for 6-O-sulfated heparins
What the sources say
- Partly supportedcites [26] Elbaum-Garfinkle, S. & Rhoades, E. Identification of an aggregation-prone structure of tau. Journal of the American Chemical Society 134, 16607–16613, https://doi.org/10.1021/ja305206m (2012). sourceExperimental — accuracy not yet measured
Our copy of Elbaum-Garfinkle & Rhoades (2012) does report a high-affinity tau-heparin interaction, but with a value of KD ≈ 20 nM from single-molecule FRET titrations at ~30 pM protein (RESULTS, 'Heparin Binding Releases Long-Range Interactions and Compacts the MTBR'), not 4.6 ± 0.6 nM. The same passage explicitly frames their 20 nM as 'significantly tighter than what has previously been reported' (refs 46,47, measured at 40-200 μM tau), so the source neither states the attributed magnitude nor presents itself as agreeing with prior nanomolar values at that level. Repeated searches of our copy (KD/affinity/titration phrasing) returned no occurrence of 4.6 ± 0.6 nM; the qualitative point — tau binds heparin with high, low-nanomolar affinity — is supported, the specific number is not. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that 6-O-sulfation is critical for tau-heparan sulfate interactions and that this modification regulates uptake in human central nervous system cell lines, iPS-derived neurons, and mouse brain slice culture.”
- Also stated in: § Cellular internalization of tau is effected by the presence of 6-O-sulfation · boosted
“These results were consistent when tested in iPS-derived neurons (Fig. 4b), demonstrating that the 6-O-sulfation motif is indeed a critical determinant for cellular tau entry.”
- Also stated in: § Cellular internalization of tau is effected by the presence of 6-O-sulfation · boosted
“Chondroitin sulfate and 6-O-desulfated heparin incubation did not reduce the median fluorescence, verifying that 6-O-sulfation is also important for tau internalization ex vivo (Fig. 4d and Supplementary Fig. 3b).”
§ Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Cellular internalization of tau is effected by the presence of 6-O-sulfation · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with our previous results, incubation with heparin, heparan sulfate, or 2-O-desulfated heparin reduced uptake of tau as quantified by the median 488 fluorescence intensity (Fig. 4d).”
§ Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) > Results > Cellular internalization of tau is effected by the presence of 6-O-sulfation
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using CRISPRi technology we have tested 3200 genes for their ability to regulate tau entry and identified enzymes in the heparan sulfate proteoglycan biosynthetic pathway as key regulators.”
- Also stated in: § Functional genomics to find modulators of tau uptake · plain
“Hits that were of particular interest included genes involved in heparan sulfate proteoglycan (HSPG) biosynthesis (EXT2 and HS6ST1) as well as DNM2, a GTPase involved in endocytosis.”
- Also stated in: § Discussion · boosted
“By screening through thousands of potential gene regulators, we have identified enzymes involved in HSPG synthesis/modification as critical modulators of tau internalization.”
§ Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Functional genomics to find modulators of tau uptake · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative binding of 6-O-desulfated heparin in the presence of 10 nM tau was 6.9% that of heparin, consistent with our hypothesis that tau interacts with the 6-O-sulfation motif on HS chains, and that HS is important for tau internalization.”
§ Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs) > Results > Tau binds to heparin derivatives and shows specificity for 6-O-sulfated heparins
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
16 more claims
Create a free account to see all 60 claims and to verify the 17 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent findings show that cell surface HSPGs mediate a large portion of neuronal uptake of Tau monomers and aggregates46,57.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous work showed that HSPGs are largely responsible for neuronal Tau uptake46–48,57.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, no tau pathology develops because apoE binding may be necessary for neuronal uptake of extracellular tau. 27”
From APOE and dementia – resequencing and genotyping in 105,597 individuals (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HSPGs are suggested to play a role in neuronal uptake of tau and in amyloid beta metabolism, and apoE binding may play an important role here. 26 , 27”
From APOE and dementia – resequencing and genotyping in 105,597 individuals (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“HSPG has been suggested to promote Aβ aggregation and neuronal uptake of extracellular tau; and ApoE-binding may be necessary for some of these effects15,16.”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [15]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728
Self-citationAlzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Rapid single-step induction of functional neurons from human pluripotent stem cells
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., Marro, S., Patzke, C., Acuna, C., Covy, J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.029 · Cited by 1,644
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036
Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., et al. (2016) · eLife · doi:10.7554/elife.19760 · Cited by 894
Self-citation
Cited by
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
“Tau uptake is regulated by HSPGs in neuronal cells, and by Chemokine CX3C receptor1 (CX3CR1) in microglia [262, 263, 265].”
BackgroundArboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598
Self-citationLRP1 is a master regulator of tau uptake and spread
Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2156-5 · Cited by 541
Self-citationReiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473
The complexity of tau in Alzheimer’s disease
Naseri, N. N., Wang, H., Guo, J., Sharma, M., & Luo, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.022 · Cited by 373
“An unbiased CRISPRi screen of 3200 genes further found that extracellular tau is taken up by micropinocytosis via the HSPG biosynthetic pathway [229] that has been shown to mediate uptake of prion proteins [218,219,230,231].”
Background
Metadata
- Authors
- Rauch, J. N., Chen, J. J., Sorum, A. W., Miller, G. M., Sharf, T., See, S. K., Hsieh-Wilson, L. C., Kampmann, M., & Kosik, K. S.
- Affiliations
- University of California, Santa Barbara (US)
- QB3 (US)
- California Institute of Technology (US)
- Corresponding author
- Kosik, Kenneth S.
- Venue
- Scientific Reports
- Published
- 2018-04-23
- Volume
- 8
- Issue
- 1
- Pages
- 6382-6382
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5913225
- OpenAlex
- W2950870451
- Cited by
- 211
- References
- 42
- Citations by year
- 2026: 20 · 2025: 28 · 2024: 13 · 2023: 21 · 2022: 20 · 2021: 39 · 2020: 38 · 2019: 23 · 2018: 9
- FWCI
- 18.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Alzheimer's Association
- National Institutes of Health (NS100717)
- University of California, Santa Barbara
- University of California, San Francisco
- National Defense Science and Engineering Graduate
- Tau Consortium
- National Institute of General Medical Sciences (T32GM007616, GM007616, T32GM064337, DP2GM119139, R01GM093627, GM119139)
- National Institute of Neurological Disorders and Stroke (U54NS100717, NS100717)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- tau protein, heparan sulfate proteoglycans, 6-O-sulfation, tau propagation, neurofibrillary tangles, Alzheimer's disease, CRISPRi screen, heparan sulfate biosynthesis, iPSC-derived neurons, brain slice culture
- MeSH terms
- Exostosin 2, Animals, Brain, Glioma, Humans, Sulfur, Tumor Cells, Cultured, Sulfotransferases, tau Proteins, N-Acetylglucosaminyltransferases, Heparan Sulfate Proteoglycans, Protein Structure, Quaternary, Genomics, Dynamin II, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). https://app.cochat.ai/papers/10.1038/s41598-018-24904-z
- The paper
- Rauch, J. N., Chen, J. J., Sorum, A. W., Miller, G. M., Sharf, T., See, S. K., Hsieh-Wilson, L. C., Kampmann, M., & Kosik, K. S. (2018). Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Scientific Reports. https://doi.org/10.1038/s41598-018-24904-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.